Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

In vitro and in vivo characterization of Recifercept, a soluble fibroblast growth factor receptor 3, as treatment for achondroplasia.

PloS one - 1 Jan 2020

Gonçalves Diogo, Rignol Guylène, Dellugat Pierre, Hartmann Guido, Sarrazy Garcia Stephanie, Stavenhagen Jeffrey, Santarelli Luca, Gouze Elvire, Czech Christian

Abstract excerpt

Achondroplasia is a rare genetic disorder caused by mutations in the Fibroblast Growth Factor receptor 3 (FGFR3). These mutations lead to aberrant increase of inhibitory signaling in proliferating chondrocytes at the growth plate. Recifercept is a potential treatment for this disease using a decoy approach to sequester FGFR3 ligands subsequently normalizing activation of the mutated FGFR3 receptor. Recifercept...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Achondroplasia
Share to Body Weight

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Bone Development

Share to Cell Differentiation

Share to Cell Proliferation

Share to Fibroblast Growth Factors

Share to Mice, Transgenic

Share to Receptor, Fibroblast Growth Factor, Type 3

Source

Open in PubMed Open full text

Identifiers

PMID: 33370388
DOI: 10.1371/journal.pone.0244368
PMCID: PMC7769458

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

In vitro and in vivo characterization of Recifercept, a soluble fibroblast growth factor receptor 3, as treatment for achondroplasia.PMID 33370388Read ↗

FGFR3 targeting strategies for achondroplasia.Semantic proximity Read ↗

Postnatal Soluble FGFR3 Therapy Rescues Achondroplasia Symptoms and Restores Bone Growth in MiceSemantic proximity Read ↗

Novel therapeutic approaches for the treatment of achondroplasia.Semantic proximity Read ↗

Achondroplasia: pathogenesis and implications for future treatment.Semantic proximity Read ↗

Fibroblast Growth Factor Receptor-3 as a Therapeutic Target for Achondroplasia - Genetic Short Limbed DwarfismSemantic proximity Read ↗

Sixteen years and counting: the current understanding of fibroblast growth factor receptor 3 (FGFR3) signaling in skeletal dysplasias.Semantic proximity Read ↗

Current and emerging therapies for Achondroplasia: The dawn of precision medicine.Semantic proximity Read ↗

Achondroplasia: from genotype to phenotype.Semantic proximity Read ↗

HDAC6 deficiency or inhibition blocks FGFR3 accumulation and improves bone growth in a model of achondroplasia.Semantic proximity Read ↗

ARQ 087 inhibits FGFR signaling and rescues aberrant cell proliferation and differentiation in experimental models of craniosynostoses and chondrodysplasias caused by activating mutations in FGFR1, FGFR2 and FGFR3.Semantic proximity Read ↗

A Lys644Glu substitution in fibroblast growth factor receptor 3 (FGFR3) causes dwarfism in mice by activation of STATs and ink4 cell cycle inhibitors.Semantic proximity Read ↗

Evaluation of the therapeutic potential of a CNP analog in a Fgfr3 mouse model recapitulating achondroplasia.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.